Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 219-223

  Moolenaar, F ^a   Meijler, W J ^b   Frijlink, H W ^a   Visser, J ^a   Proost, J H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Morphine sulphate; MS Contin; Rectal absorption

Indexed keywords

MORPHINE SULFATE; PARACETAMOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPOSITORY; TABLET;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; NEOPLASMS; PAIN, INTRACTABLE; SUPPOSITORIES;

EID: 0033945563     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000133     Document Type: Article

References (18)

1. 1. Maloney CM, Kesner RK, Klein G, Bockenstett J (1989) The rectal administration of MS Contin: clinical implications of use in end stage cancer. Am J Hospice Care 6: 34-35
2. 2. Wilkinson TJ, Robinson BA, Begg EJ, Dufull SB, Ravenscroft PJ, Schneider JJ (1992) Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 31: 251-254
3. 3. Moolenaar F, Meijler WJ, Frijlink HW, Jauw TH, Visser J, Proost JH (1995) Rectal absorption of morphine from controlled release suppositories. Int J Pharmacol 114: 117-120
4. 4. Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC (1995) Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Pharmacol 35: 666-672
5. 5. Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D (1998) Comparative efficacy and safety of controlled release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 38: 74-81
6. 6. Todd RD, Muldoon SM, Watson RL (1982) Determination of morphine in cerebrospinal fluid and plasma by HPLC with electrochemical detection. J Chromatogr 232: 101-110
7. 7. Hauschke D, Steinijans VW, Diletti E (1990) A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28: 72-78
8. 8. Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577-584
9. 9. Goucke CR, Hackett LP, Ilett KF (1994) Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 56: 145-149
10. 10. Gardmark M, Karlsson MO, Hammarlund-Udenaes M (1998) Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling. J Pharm Sci 87: 813-820
11. 11. Osborne R, Joel S, Trew D, Slevin M (1990) Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47: 12-19
12. 12. Vermeire A, Remon JP, Rosseel MT, Belpaire F, Devulder J, Bogaert MG (1998) Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol 53: 325-330
13. 13. Hoskin PJ, Hanks GW (1990) Morphine: pharmacokinetics and clinical practice. Br J Cancer 62: 705-707
14. 14. Skopp G, Putsch L, Ganssmann B, Aderjan R, Mattern R (1998) A preliminary study on the distribution of morphine and its glucuronides in the subcompartments of blood. J Anal Toxicol 22: 261-264
15. 15. Du X, Skopp G, Aderjan R (1999) The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulphate suppositories. Ther Drug Monit 21: 208-214
16. 16. Faura CC, Moore RA, Horga JF, Hand CW, McQuay HJI (1996) Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 11: 95-102
17. 17. Wolff T, Samuelsson H, Hedner T (1996) Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain 68: 209-216
18. 18. van Dongen RT, Crul BJ, Koopman-Kimenai PM, Vree TB (1994) Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br J Clin Pharmacol 38: 271-273